Companies
Tofflon
a lyophilizer leader with roughly 60% of China's mid-to-high-end market, now building 10–15,000 L stainless bioreactors with PAT sensors; it reported about 5.23 billion yuan of 2025 revenue and leads an MIIT high-performance-bioreactor project (30 IP filings, 5 patents).
- Country
- China
- Ticker
- SHE: 300171
FDA GMP
ISO 9001
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| analytics-pat | ✓ | ✓ | — | ✓ |
| fill-finish-packaging | ✓ | ✓ | — | ✓ |
| therapeutics-platforms | ✓ | ✓ | — | ✓ |
| upstream-bioreactors | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaefsamoa-chinaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $8M from venture and corporate backers (2026-08-31) | medbot.cn |
| Founded | 1993 in Shanghai (2026-08-31) | medbot.cn |
| Headquarters | Shanghai, China (1509 Duhui Road) (2026-08-31) | disc.static.szse.cn · en.tofflon.com |
| Production site | 8 global manufacturing bases (2026-08-31) | medbot.cn |
| Capacity | Stainless steel bioreactors/fermenters up to 20,000L and single-use bioreactors up to 2,000L (2026-08-31) | dcvmn.org |
| Certification | CNAS accreditation and GLP system (2026-08-31) | en.tofflon.com |
| Regulatory approval | Provides consulting/compliance services for US FDA, EU GMP, China GMP, Australia TGA, and WHO standards (2026-08-31) | tofflon.com |
| Revenue | 5.20 billion (TTM Q1 2026) (2026-03-31) | siriusinvestors.com |
Independent sources: dcvmn.org · disc.static.szse.cn · medbot.cn · siriusinvestors.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Aseptic filling lines | fill-finish-packaging | Low | → |
| Bioprocess analytics & PAT (process analytical technology) | analytics-pat | Low | → |
| Fill-finish & aseptic biomanufacturing | therapeutics-platforms | Low | → |
| Lyophilizers and freeze dryers | fill-finish-packaging | Low | → |
| Single-use bag bioreactors (50L-2000L) | upstream-bioreactors | Low | → |
| Solid-state fermentation bioreactors | upstream-bioreactors | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.